ORLANDO, FL. (February 22, 2022) – MicroGenDX continues to lead the DNA diagnostics industry as it adds New York state’s approved lab permit for NGS diagnostics and qPCR microbial identification for 15 antimicrobial resistance genes. This will now allow residents of New York state to utilize the latest DNA-based infection diagnosis and treatment technologies offered by MicroGenDX, and help resolve chronic infections that have resisted treatment and perpetuated patient suffering.
“Our diagnostic lab has received approval in every other state in the U.S.,” says Rick Martin, CEO of MicroGenDX, “and we have wanted patients in New York state to benefit from this highly effective NGS technology for several years. With a lot of hard work from our team, we have satisfied New York’s lab permit requirements and are thrilled to offer New York’s residents access to this revolutionary diagnostic testing.”
The New York permit approval process has required compliance with rigorous operating and proficiency standards for bacteriology and mycology laboratories. The permit became effective February 17, 2022.
Founded in 2008, MicroGenDX has become the industry leader in rapid turnaround and affordability for comprehensive Next-Generation Sequencing (NGS) and qPCR testing for clinical diagnostics. MicroGenDX is CLIA-licensed and CAP-accredited, and has been the trusted research partner for the CDC, U.S. Army, NASA and the FDA. MicroGenDX has published over 35 clinical trials and is the most experienced molecular diagnostic laboratory with some 1.5 million samples processed.
Name: James R. Compagno Email: [email protected] Job Title: Director of Marketing
Google News, Menafn, IPS, Financial Content, Reportedtimes, ReleaseLive, PR-Wirein, CE, iCN Internal Distribution, Extended Distribution, English